Researchers at UCLA Health’s Jonsson Comprehensive Cancer Center have identified a molecular pathway that appears to help drive T-cell exhaustion, a major obstacle to durable cancer immunotherapy. In a study published in Cancer Immunology Research, the team reported that blocking the Cullin-5 RING E3 ligase complex, known as CRL5, helped engineered immune cells remain active longer and produce stronger antitumor responses in preclinical models.
The finding is significant because many cancer treatments depend on T cells maintaining their ability to recognize and kill tumor cells over extended periods. When those cells become exhausted, their cancer-fighting activity declines. Tumors can then resume growth or evade immune control.
Why T-cell exhaustion matters
T cells are central to several forms of cancer immunotherapy, including CAR T-cell therapy, tumor-infiltrating lymphocyte therapy and T-cell receptor-engineered approaches. These treatments can produce powerful responses, but maintaining that activity is especially difficult in solid tumors.
In these settings, T cells can face persistent exposure to tumor-derived signals. Over time, that sustained stimulation can reduce their ability to function effectively. The UCLA researchers describe T-cell exhaustion as one of the principal reasons immunotherapies can lose effectiveness or fail to generate lasting responses.
“Immunotherapy depends on T cells staying active long enough to continuously recognize and kill cancer cells,” Justin Saco, a graduate student in the laboratory of UCLA researcher Antoni Ribas and first author of the study, said in the university’s account of the research. The practical implication is straightforward: extending T-cell function could improve the chance of durable tumor control.
A genome-wide search under repeated tumor exposure
The team used a genome-wide CRISPR screen in human CD8-positive T cells engineered to recognize a melanoma antigen. CRISPR screening allows researchers to systematically switch off large numbers of genes and observe how those changes affect cell behavior.
Rather than examining cells only after a single interaction with a tumor, the researchers repeatedly exposed the engineered T cells to tumor cells in laboratory experiments. That design was intended to model the prolonged stimulation that can contribute to exhaustion in cancer.
Through that screen, the investigators identified the CRL5 pathway as a key regulator. CRL5 is an E3 ubiquitin ligase complex, part of the cellular machinery involved in marking proteins for regulation or degradation. The work links this pathway to the loss of sustained T-cell performance under repeated tumor challenge.
What blocking CRL5 changed
When the pathway was blocked, engineered T cells stayed active longer, generated stronger antitumor responses and resisted exhaustion in the study’s preclinical models. Those results point to CRL5 as a possible target for improving the persistence of cell-based immunotherapies.
The research does not establish a new treatment for patients, and it does not show that CRL5 inhibition will be safe or effective in clinical use. It instead provides a biological lead: a pathway that may help explain why otherwise capable cancer-fighting cells lose momentum in hostile tumor environments.
That distinction is important. Immunotherapies can face several barriers in solid tumors, from the physical and biochemical environment around the cancer to the repeated signals that alter immune-cell behavior. A pathway that helps preserve T-cell function could potentially be combined with other strategies designed to improve cell trafficking, tumor recognition or survival.
Potential relevance for engineered-cell therapies
The UCLA team says the discovery could inform efforts to develop longer-lasting immunotherapies for solid tumors, including CAR T-cell therapies and other adoptive cell therapies. Adoptive approaches generally involve preparing or engineering immune cells so that they can better recognize cancer, then using those cells as a treatment.
CAR T-cell therapy has demonstrated major clinical impact in some blood cancers, but translating comparable durability to solid tumors remains difficult. The new study focuses on one reason: immune cells may become functionally depleted after continued exposure to their target.
If later research validates the mechanism and finds a practical way to act on it, CRL5 could become part of a broader effort to design T cells that are more resilient from the outset. For now, the work adds a defined molecular candidate to a complex problem and offers a basis for follow-up studies in additional models and, eventually, clinical research.
A research step, not a clinical conclusion
The study’s strongest claim is mechanistic and preclinical. It identifies CRL5 as a pathway associated with T-cell exhaustion and reports improved performance when that pathway was blocked in the researchers’ models. Whether the same intervention can be translated into an approved therapy will depend on further work on safety, delivery, effectiveness and patient outcomes.
Even so, the result addresses a central challenge in cancer immunotherapy: getting immune cells to keep working long enough to control a tumor. By using a genome-wide CRISPR screen under repeated tumor exposure, the UCLA researchers have highlighted a possible route toward more persistent engineered T cells.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
